{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:36:32Z","timestamp":1793108192405,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Diagnosing multiple sclerosis (MS) is challenging due to diverse symptoms and the absence of specific biomarkers. Concurrent autoimmune diseases (AID) or non-specific antibodies further complicate diagnosis, progression monitoring, and management. Data on AID prevalence in MS patients are sparse. This study aims to identify concurrent AIDs alongside MS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective single-center study, we analyzed patient records at our university hospital from 2010 to 2017, focusing on cases suspected of inflammatory demyelinating disease. The 2017 McDonald criteria were applied. Additionally, we measured neurofilament light (NfL) levels from available CSF samples in our biobank.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified a total of 315 patients, of whom 66% were women. In total, 13.7% of all patients had concurrent AID, while 20.3% had isolated antibody findings without AID. The most common AID was autoimmune thyroiditis (8.9%), followed by chronic inflammatory skin diseases (1.6%), arthritis (1%), type 1 diabetes (1%), Sj\u00f6gren\u2019s syndrome (0.6%), and inflammatory bowel diseases (0.6%). Cardiolipin antibodies were the most frequent isolated antibody\u00a0finding (8.6%). Our data showed that, from the perspective of the initial demyelinating event, neither comorbid AID nor isolated antibodies significantly influenced relapses or MS progression over a median follow-up of 9\u00a0months. Standard CSF parameters and NfL levels were similar between the groups at the time of MS diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study shows that AIDs, particularly autoimmune thyroiditis, frequently occur at the onset of MS. The proportion of AIDs commonly treated with immunomodulatory therapy in our cohort was similar to that observed in the general population. Comorbid AID did not affect NfL levels, indicating similar disease activity. Future research should explore new AID emergence during the course of MS, especially considering the increased incidence of rheumatic diseases later in life.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42466-024-00351-2","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T09:25:52Z","timestamp":1731403552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prevalence of comorbid autoimmune diseases and antibodies in newly diagnosed multiple sclerosis patients"],"prefix":"10.1186","volume":"6","author":[{"given":"Konstantin Fritz","family":"Jendretzky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"Lezius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz Felix","family":"Konen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus Emre","family":"G\u00fczeloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Skuljec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Peter","family":"Wattjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8550-335X","authenticated-orcid":false,"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"issue":"4","key":"351_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang, L., Wang, F.-S., & Gershwin, M. E. (2015). Human autoimmune diseases: A comprehensive update. Journal of Internal Medicine, 278(4), 369\u2013395. https:\/\/doi.org\/10.1111\/joim.12395","journal-title":"Journal of Internal Medicine"},{"issue":"14","key":"351_CR2","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., Robertson, N., La Rocca, N., Uitdehaag, B., van der Mei, I., Wallin, M., Helme, A., Napier, C. A., Rijke, N., & Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal, 26(14), 1816\u20131821. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"351_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018). Multiple sclerosis. New England Journal of Medicine, 378(2), 169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"351_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"WI McDonald","year":"2001","unstructured":"McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H.-P., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., Sandberg-Wollheim, M., Sibley, W., Thompson, A., Van Den Noort, S., Weinshenker, B. Y., & Wolinsky, J. S. (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology, 50(1), 121\u2013127. https:\/\/doi.org\/10.1002\/ana.1032","journal-title":"Annals of Neurology"},{"issue":"6","key":"351_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"CH Polman","year":"2005","unstructured":"Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H.-P., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O\u2019Connor, P. W., Sandberg-Wollheim, M., Thompson, A. J., Weinshenker, B. G., & Wolinsky, J. S. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d Annals of Neurology, 58(6), 840\u2013846. https:\/\/doi.org\/10.1002\/ana.20703","journal-title":"Annals of Neurology"},{"issue":"2","key":"351_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Montalban, X., O\u2019Connor, P., Sandberg-Wollheim, M., Thompson, A. J., Waubant, E., Weinshenker, B., & Wolinsky, J. S. (2011). Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 69(2), 292\u2013302. https:\/\/doi.org\/10.1002\/ana.22366","journal-title":"Annals of Neurology"},{"issue":"2","key":"351_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K., Galetta, S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller, D. H., Montalban, X., \u2026 Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"The Lancet Neurology"},{"issue":"6","key":"351_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1474-4422(18)30160-1","volume":"17","author":"P Schwenkenbecher","year":"2018","unstructured":"Schwenkenbecher, P., Wurster, U., S\u00fchs, K.-W., Stangel, M., & Skripuletz, T. (2018). Applying the 2017 McDonald diagnostic criteria for multiple sclerosis. The Lancet Neurology, 17(6), 498. https:\/\/doi.org\/10.1016\/S1474-4422(18)30160-1","journal-title":"The Lancet Neurology"},{"issue":"11","key":"351_CR9","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/jamaneurol.2018.2160","volume":"75","author":"V Der Vuurst","year":"2018","unstructured":"Der Vuurst, V., De Vries, R. M., Mescheriakova, J. Y., Wong, Y. Y. M., Runia, T. F., Jafari, N., Samijn, J. P., De Beukelaar, J. W. K., Wokke, B. H. A., Siepman, T. A. M., & Hintzen, R. Q. (2018). Application of the 2017 revised McDonald criteria for multiple sclerosis to patients with a typical clinically isolated syndrome. JAMA Neurology, 75(11), 1392. https:\/\/doi.org\/10.1001\/jamaneurol.2018.2160","journal-title":"JAMA Neurology"},{"key":"351_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00636","author":"L Michel","year":"2015","unstructured":"Michel, L., Touil, H., Pikor, N. B., Gommerman, J. L., Prat, A., & Bar-Or, A. (2015). B Cells in the multiple sclerosis central nervous system: Trafficking and contribution to CNS-compartmentalized inflammation. Frontiers in Immunology. https:\/\/doi.org\/10.3389\/fimmu.2015.00636","journal-title":"Frontiers in Immunology"},{"issue":"13","key":"351_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1212\/WNL.0000000000003152","volume":"87","author":"AJ Solomon","year":"2016","unstructured":"Solomon, A. J., Bourdette, D. N., Cross, A. H., Applebee, A., Skidd, P. M., Howard, D. B., Spain, R. I., Cameron, M. H., Kim, E., Mass, M. K., Yadav, V., Whitham, R. H., Longbrake, E. E., Naismith, R. T., Wu, G. F., Parks, B. J., Wingerchuk, D. M., Rabin, B. L., Michel Toledano, W., \u2026 Weinshenker, B. G. (2016). The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology, 87(13), 1393\u20131399. https:\/\/doi.org\/10.1212\/WNL.0000000000003152","journal-title":"Neurology"},{"issue":"9","key":"351_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nrneurol.2017.106","volume":"13","author":"AJ Solomon","year":"2017","unstructured":"Solomon, A. J., & Corboy, J. R. (2017). The tension between early diagnosis and misdiagnosis of multiple sclerosis. Nature Reviews Neurology, 13(9), 567\u2013572. https:\/\/doi.org\/10.1038\/nrneurol.2017.106","journal-title":"Nature Reviews Neurology"},{"issue":"8","key":"351_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1474-4422(23)00148-5","volume":"22","author":"AJ Solomon","year":"2023","unstructured":"Solomon, A. J., Arrambide, G., Brownlee, W. J., Flanagan, E. P., Amato, M. P., Amezcua, L., Banwell, B. L., Barkhof, F., Corboy, J. R., Correale, J., Fujihara, K., Graves, J., Harnegie, M. P., Hemmer, B., Lechner-Scott, J., Marrie, R. A., Newsome, S. D., Rocca, M. A., Royal, W., & Cohen, J. A. (2023). Differential diagnosis of suspected multiple sclerosis: An updated consensus approach. The Lancet Neurology, 22(8), 750\u2013768. https:\/\/doi.org\/10.1016\/S1474-4422(23)00148-5","journal-title":"The Lancet Neurology"},{"issue":"6","key":"351_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/aje\/kwn408","volume":"169","author":"EC Somers","year":"2009","unstructured":"Somers, E. C., Thomas, S. L., Smeeth, L., & Hall, A. J. (2009). Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? American Journal of Epidemiology, 169(6), 749\u2013755. https:\/\/doi.org\/10.1093\/aje\/kwn408","journal-title":"American Journal of Epidemiology"},{"issue":"1","key":"351_CR15","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a029637","volume":"8","author":"M Hiltensperger","year":"2018","unstructured":"Hiltensperger, M., & Korn, T. (2018). The interleukin (IL)-23\/T helper (Th)17 axis in experimental autoimmune encephalomyelitis and multiple sclerosis. Cold Spring Harbor Perspectives in Medicine, 8(1), a029637. https:\/\/doi.org\/10.1101\/cshperspect.a029637","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"351_CR16","doi-asserted-by":"publisher","first-page":"1197195","DOI":"10.3389\/fimmu.2023.1197195","volume":"14","author":"RA Marrie","year":"2023","unstructured":"Marrie, R. A., Fisk, J. D., Fitzgerald, K., Kowalec, K., Maxwell, C., Rotstein, D., Salter, A., & Tremlett, H. (2023). Etiology, effects and management of comorbidities in multiple sclerosis: Recent advances. Frontiers in Immunology, 14, 1197195. https:\/\/doi.org\/10.3389\/fimmu.2023.1197195","journal-title":"Frontiers in Immunology"},{"key":"351_CR17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24294","author":"Z Barkhane","year":"2022","unstructured":"Barkhane, Z., Elmadi, J., Satish Kumar, L., Pugalenthi, L. S., Ahmad, M., & Reddy, S. (2022). Multiple sclerosis and autoimmunity: A veiled relationship. Cureus. https:\/\/doi.org\/10.7759\/cureus.24294","journal-title":"Cureus"},{"key":"351_CR18","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2023.0038","author":"S Wawrzyniak","year":"2023","unstructured":"Wawrzyniak, S., Rakoca, M., Ku\u0142akowska, A., Bartosik-Psujek, H., Koziarska, D., Kapica-Topczewska, K., Kubicka-B\u0105czyk, K., & Adamczyk-Sowa, M. (2023). Multiple sclerosis and autoimmune diseases\u2014A case control study. Neurologia i Neurochirurgia Polska. https:\/\/doi.org\/10.5603\/PJNNS.a2023.0038","journal-title":"Neurologia i Neurochirurgia Polska"},{"issue":"6","key":"351_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065385","volume":"8","author":"AJ Solomon","year":"2013","unstructured":"Solomon, A. J., Hills, W., Chen, Z., Rosenbaum, J., Bourdette, D., & Whitham, R. (2013). Autoantibodies and Sjogren\u2019s syndrome in multiple sclerosis, a reappraisal. PLoS ONE, 8(6), e65385. https:\/\/doi.org\/10.1371\/journal.pone.0065385","journal-title":"PLoS ONE"},{"key":"351_CR20","unstructured":"Hemmer, B., Bayas, A., & Domurath, B. (2023). Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie, 2023. www.dgn.org\/leitlinien"},{"key":"351_CR21","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2023.0047","author":"S \u00d6ncel","year":"2023","unstructured":"\u00d6ncel, S., Dalk\u0131l\u0131\u00e7, \u015e, Sayan, S., Darol, E., Zafer, A., Kara, D., & Tun\u00e7, A. (2023). Clinical significance and prognostic value of serum autoantibody tests in multiple sclerosis. Neurologia i Neurochirurgia Polska. https:\/\/doi.org\/10.5603\/PJNNS.a2023.0047","journal-title":"Neurologia i Neurochirurgia Polska"},{"issue":"3","key":"351_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/ane.13054","volume":"139","author":"A Dal-Bianco","year":"2019","unstructured":"Dal-Bianco, A., Wenhoda, F., Rommer, P. S., Weber, M., Altmann, P., Kraus, J., Leutmezer, F., & Salhofer-Polanyi, S. (2019). Do elevated autoantibodies in patients with multiple sclerosis matter? Acta Neurologica Scandinavica, 139(3), 238\u2013246. https:\/\/doi.org\/10.1111\/ane.13054","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"351_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1034\/j.1600-0404.2001.104002083.x","volume":"104","author":"C De Andr\u00e9s","year":"2001","unstructured":"De Andr\u00e9s, C., Guillem, A., Rodr\u00edguez-Mahou, M., & L\u00f3pez Longo, F. J. (2001). Frequency and significance of anti-Ro (SS-A) antibodies in multiple sclerosis patients: Anti-Ro in MS. Acta Neurologica Scandinavica, 104(2), 83\u201387. https:\/\/doi.org\/10.1034\/j.1600-0404.2001.104002083.x","journal-title":"Acta Neurologica Scandinavica"},{"issue":"1\u20132","key":"351_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jneuroim.2007.04.008","volume":"187","author":"N Garg","year":"2007","unstructured":"Garg, N., Zivadinov, R., Ramanathan, M., Vasiliu, I., Locke, J., Watts, K., Lema, J., Rajeswary, J., Munschauer, F. E., Ambrus, J., & Weinstock-Guttman, B. (2007). Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. Journal of Neuroimmunology, 187(1\u20132), 159\u2013165. https:\/\/doi.org\/10.1016\/j.jneuroim.2007.04.008","journal-title":"Journal of Neuroimmunology"},{"issue":"9","key":"351_CR25","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3390\/ijms17091592","volume":"17","author":"P Schwenkenbecher","year":"2016","unstructured":"Schwenkenbecher, P., Sarikidi, A., Wurster, U., Bronzlik, P., S\u00fchs, K.-W., Raab, P., Stangel, M., Pul, R., & Skripuletz, T. (2016). McDonald criteria 2010 and 2005 compared: Persistence of high oligoclonal band prevalence despite almost doubled diagnostic sensitivity. International Journal of Molecular Sciences, 17(9), 1592. https:\/\/doi.org\/10.3390\/ijms17091592","journal-title":"International Journal of Molecular Sciences"},{"issue":"10","key":"351_CR26","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.3390\/ijms18102061","volume":"18","author":"P Schwenkenbecher","year":"2017","unstructured":"Schwenkenbecher, P., Sarikidi, A., B\u00f6nig, L., Wurster, U., Bronzlik, P., S\u00fchs, K.-W., Pul, R., Stangel, M., & Skripuletz, T. (2017). Clinically isolated syndrome according to McDonald 2010: Intrathecal IgG synthesis still predictive for conversion to multiple sclerosis. International Journal of Molecular Sciences, 18(10), 2061. https:\/\/doi.org\/10.3390\/ijms18102061","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"351_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1474-4422(23)00112-6","volume":"22","author":"S Gingele","year":"2023","unstructured":"Gingele, S., Jendretzky, K. F., Bajor, A., Meuth, S. G., & Skripuletz, T. (2023). Application of diagnostic criteria for optic neuritis. The Lancet Neurology, 22(5), 375\u2013376. https:\/\/doi.org\/10.1016\/S1474-4422(23)00112-6","journal-title":"The Lancet Neurology"},{"issue":"2","key":"351_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., Jarius, S., Lana-Peixoto, M., Levy, M., Simon, J. H., Tenembaum, S., Traboulsee, A. L., Waters, P., Wellik, K. E., & Weinshenker, B. G. (2015). International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 85(2), 177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"3","key":"351_CR29","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell, B., Bennett, J. L., Marignier, R., Kim, H. J., Brilot, F., Flanagan, E. P., Ramanathan, S., Waters, P., Tenembaum, S., Graves, J. S., Chitnis, T., Brandt, A. U., Hemingway, C., Neuteboom, R., Pandit, L., Reindl, M., Saiz, A., Sato, D. K., Rostasy, K., & Palace, J. (2023). Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria. The Lancet Neurology, 22(3), 268\u2013282. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8","journal-title":"The Lancet Neurology"},{"issue":"1","key":"351_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., De Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., Kleiter, I., K\u00fcmpfel, T., Levy, M., Palace, J., Ruprecht, K., Saiz, A., Trebst, C., Weinshenker, B. G., & Wildemann, B. (2018). MOG encephalomyelitis: International recommendations on diagnosis and antibody testing. Journal of Neuroinflammation, 15(1), 134. https:\/\/doi.org\/10.1186\/s12974-018-1144-2","journal-title":"Journal of Neuroinflammation"},{"issue":"2","key":"351_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/clinchem\/41.2.256","volume":"41","author":"H Reiber","year":"1995","unstructured":"Reiber, H. (1995). External quality assessment in clinical neurochemistry: Survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF\/serum quotients. Clinical Chemistry, 41(2), 256\u2013263.","journal-title":"Clinical Chemistry"},{"key":"351_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/135245859800400302","volume":"4","author":"H Reiber","year":"1998","unstructured":"Reiber, H. (1998). Cerebrospinal fluid\u2014Physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Multiple Sclerosis Journal, 4, 99\u2013107. https:\/\/doi.org\/10.1177\/135245859800400302","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"351_CR33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","volume":"57","author":"M Andersson","year":"1994","unstructured":"Andersson, M., Alvarez-Cermeno, J., Bernardi, G., Cogato, I., Fredman, P., Frederiksen, J., Fredrikson, S., Gallo, P., Grimaldi, L. M., Gronning, M., Keir, G., Lamers, K., Link, H., Magalhaes, A., Massaro, A. R., Ohman, S., Reiber, H., Ronnback, L., Schluep, M., & Wurster, U. (1994). Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. Journal of Neurology, Neurosurgery & Psychiatry, 57(8), 897\u2013902. https:\/\/doi.org\/10.1136\/jnnp.57.8.897","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"5","key":"351_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103312","volume":"22","author":"FF Konen","year":"2023","unstructured":"Konen, F. F., M\u00f6hn, N., Witte, T., Schefzyk, M., Wiestler, M., Lovric, S., Hufendiek, K., Schwenkenbecher, P., S\u00fchs, K.-W., Friese, M. A., Klotz, L., Pul, R., Pawlitzki, M., Hagin, D., Kleinschnitz, C., Meuth, S. G., & Skripuletz, T. (2023). Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. Autoimmunity Reviews, 22(5), 103312. https:\/\/doi.org\/10.1016\/j.autrev.2023.103312","journal-title":"Autoimmunity Reviews"},{"key":"351_CR35","doi-asserted-by":"publisher","unstructured":"Holstiege, J., Klimke, K., Akmatov, M. K., Kohring, C., Dammertz, L., & B\u00e4tzing, J. (2021). Bundesweite Verordnungstrends biologischer Arzneimittel bei h\u00e4ufigen Autoimmunerkrankungen, 2012 bis 2018. https:\/\/doi.org\/10.20364\/VA-21.03","DOI":"10.20364\/VA-21.03"},{"key":"351_CR36","doi-asserted-by":"publisher","unstructured":"Marin, G. G., Cardiel, M. H., Cornejo, H., & Viveros, M. E. (2009). Prevalence of Antinuclear Antibodies in 3 Groups of Healthy Individuals: Blood Donors, Hospital Personnel, and Relatives of Patients With Autoimmune Diseases. JCR: Journal of Clinical Rheumatology, 15(7), 325. https:\/\/doi.org\/10.1097\/RHU.0b013e3181bb971b","DOI":"10.1097\/RHU.0b013e3181bb971b"},{"key":"351_CR37","doi-asserted-by":"publisher","first-page":"E256","DOI":"10.1055\/s-0043-115429","volume":"01","author":"J Becker","year":"2017","unstructured":"Becker, J., Geffken, M., Diehl, R. R., Berlit, P., & Kr\u00e4mer, M. (2017). Choosing wisely? Multiple sclerosis and laboratory screening for autoimmune differential diagnoses. Neurology International Open, 01, E256\u2013E263. https:\/\/doi.org\/10.1055\/s-0043-115429","journal-title":"Neurology International Open"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-024-00351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-024-00351-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-024-00351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T22:04:23Z","timestamp":1731449063000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-024-00351-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1186\/s42466-024-00351-2","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committee (no. 8172-BO-K-2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest. Outside the submitted work, the authors received honoraria for lectures, travel grants, or research grants. KFJ received research support from Else Kr\u00f6ner Fresenius Foundation and travel compensation and congress fee from Merck and Novartis. TT received honoraria from Boehringer Ingelheim, Janssen and Galapagos. LML reports no disclosures. FFK received travel grants from Merck and Novartis. AH reports no disclosures. LH reports no disclosures. YEG reports no disclosures. PS reports no disclosures. KWS reports honoraria for lectures or travel reimbursements for attending meetings from Biogen, Merck, Bavarian Nordic and Bristol-Myers Squibb as well as research support from Bristol-Myers Squibb. JS received lecture fees from Merck and Sanofi, and travel grant from Novartis and Sanofi. MPW received speaker or consultancy honoraria from Alexion, Bayer Healthcare, Biogen, Biologix, Bristol Myers Squibb, Celgene, Genilac, Imcyse, IXICO, Icometrix, Medison, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and publication royalties from Springer and Elsevier. TW reports honoraria for lectures and travel grants from Abbvie, Biogen, Boehringer Ingelheim, Celgene, Chugai, CSL Behring, Euroimmun, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, Siemens, Takeda, UCB. CK received lecture and consultancy fees from Biogen, Roche, and Novartis. RP received honoraria for lecturing and consulting from Alexion, Bayer Healthcare, Biogen, Bristol-Mayers Squibb, Hexal, Merck Serono, Mylan, Novartis, Roche, Sanofi Genzyme. He received research funds from Merck Serono and Novartis. HT has participated in meetings sponsored by or received honoraria for acting as an advisor\/speaker for Alexion, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Diamed, Fresenius, Fujirebio, GlaxoSmithKline, Horizon, Janssen-Cilag, Merck, Novartis, Roche, Sanofi-Genzyme, Siemens, and Teva. All not related to the present work. SG received consulting and\/or speaker honoraria from Alexion, Alnylam Pharmaceuticals, AstraZeneca, GSK, Pfizer and Merck. His research is supported by the Deutsche Forschungsgemeinschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Hannover Biomedical Research School (HBRS), Alnylam Pharmaceuticals and CSL Behring. TS reports research support from Alnylam Pharmaceuticals, CSL Behring, Novartis, Siemens; honoraria for lectures and travel expenses for attending meetings from Alexion, Alnylam Pharmaceuticals, argenx, Bayer Vital, Biogen, Bristol Myers Squibb, Celgene, Centogene, CSL Behring, Euroimmun, Grifols, Hexal AG, Horizon, Janssen-Cilag, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Siemens, Swedish Orphan Biovitrum, Teva, Viatris; consultant fees from Alexion, Alnylam Pharmaceuticals, Biogen, Centogene, CSL Behring, Grifols, Hexal AG, Janssen-Cilag, Merck Serono, Novartis, Roche, Sanofi, Swedish Orphan Biovitrum, Viatris.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}